🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
13.66
-0.50 (-3.53%)
At close: Nov 20, 2026, 4:00 PM EST
13.70
+0.04 (0.29%)
After-hours: Nov 20, 2026, 7:30 PM EST

Mineralys Therapeutics Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, Mineralys Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $43.56. The average 1-year stock price forecast is 218.89% higher than the current stock price, while the lowest is $19 (+39.09%) and the highest is $56 (+309.96%).

Price Target: $43.56 (+218.89%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$19$43.56$52$56
Change+39.09%+218.89%+280.67%+309.96%

Analyst Ratings

The average analyst rating for Mineralys Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMay '26Jun '26Jul '26Aug '26Oct '26Nov '26
Strong Buy999999
Buy000000
Hold111122
Sell000000
Strong Sell000000
Total101010101111

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$56
BuyReiterates$56+309.96%Nov 9, 2026
UBS
UBS
Hold
Reiterates
$29 → $19
HoldReiterates$29 → $19+39.09%Nov 6, 2026
Wells Fargo
Wells Fargo
Buy
Maintains
$55
BuyMaintains$55+302.64%Nov 6, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aNov 5, 2026
TD Cowen
TD Cowen
Buy
Maintains
n/a
BuyMaintainsn/an/aNov 5, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
n/a
Revenue Next Year
84.31M
EPS This Year
-4.58
from -2.29
EPS Next Year
-2.66
from -4.58
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
------
Operating Income
-18.73M-31.48M-84.66M-192.40M-170.60M-400.60M
Net Income
-19.41M-29.80M-71.90M-177.81M-154.65M-391.14M
EPS
-----2.29-4.58
Free Cash Flow
-----142.43M-382.26M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
Highn/a
Avgn/a
Lown/a

Revenue Growth

Revenue Growth20272028
High-
Avg-
Low-

EPS Forecast

EPS202620272028
High-4.26
Avg-4.58
Low-4.82

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-